Edna F. Choo

3.5k citations

54 papers · 1.9k indexed · h-index 24

Molecular Biology top 10%
Oncology top 5%
Pharmacology top 1%
Pediatrics, Perinatology and Child Health top 5%
Computational Theory and Mathematics top 2%

Co-authors: G. Wilkinson Richard B. Kim Alastair J.J. Wood Hitoshi Imamura Brenda F. Leake Jason Boggs Marcia Belvin Mark Merchant
Topics: Melanoma and MAPK Pathways (20 papers)Pharmacogenetics and Drug Metabolism (12 papers)PI3K/AKT/mTOR signaling in cancer (9 papers)
Cited by: Pharmacology Oncology Virology
Journals: Cancer Research Clinical Cancer Research Journal of Medicinal Chemistry
Partner nations: United States Canada France

In The Last Decade

Edna F. Choo

53 papers receiving 1.9k citations

Peers

Countries citing papers authored by Edna F. Choo

Since Specialization

Citations

This map shows the geographic impact of Edna F. Choo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edna F. Choo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edna F. Choo more than expected).

Fields of papers citing papers by Edna F. Choo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edna F. Choo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edna F. Choo. The network helps show where Edna F. Choo may publish in the future.

Co-authorship network of co-authors of Edna F. Choo

This figure shows the co-authorship network connecting the top 25 collaborators of Edna F. Choo. A scholar is included among the top collaborators of Edna F. Choo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edna F. Choo. Edna F. Choo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bioactivation of α,β-Unsaturated Carboxylic Acids Through Acyl Glucuronidation 2020 ·Drug Metabolism and Disposition ·(unknown),Sudheer Bobba,Kevin M. Johnson,Jessica M. Grandner,Wei Wang,Chenghong Zhang,Jingwei Cai,Edna F. Choo,S. Cyrus Khojasteh,Donglu Zhang	9
2	Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models 2020 ·Haematologica ·Raghuveer Singh Mali,Qi Zhang,RosaAnna DeFilippis,Antonio Cavazos,Vinitha M. Kuruvilla,(unknown),Vidhi Mody,Edna F. Choo,Monique Dail,Neil P. Shah,Marina Konopleva,Deepak Sampath,Elisabeth A. Lasater	97
3	Practical strategies when using a stable isotope labeled microtracer for absolute bioavailability assessment: A case study of a high oral dose clinical candidate GDC-0810 2018 ·Journal of Pharmaceutical and Biomedical Analysis ·Buyun Chen,(unknown),(unknown),Yang Gao,Edna F. Choo,Kevin DeMent,(unknown),Kelly Zhang,(unknown),Lichuan Liu,Brian Dean,Yuzhong Deng	2
4	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer 2017 ·Cancer Research ·Lingyan Jin,(unknown),Emily Chan,(unknown),Ehud Segal,Mark Merchant,Samir Kharbanda,Ryan Raisner,Peter M. Haverty,Zora Modrušan,Justin Q. Ly,Edna F. Choo,Susan Kaufman,Maureen H. Beresini,F. Anthony Romero,Steven Magnuson,Karen E. Gascoigne	105
5	Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs 2016 ·Xenobiotica ·Ryan Takahashi,Shuguang Ma,Qin Yue,(unknown),Yijun Yi,Justin Q. Ly,Jason Boggs,Alec Fettes,Andrew McClory,Yuzhong Deng,Cornelis E. C. A. Hop,S. Cyrus Khojasteh,Edna F. Choo	7
6	A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth 2013 ·Cancer Research ·Ted Lau,Emily Chan,Marinella Callow,Jo Waaler,Jason Boggs,Robert A. Blake,Steven Magnuson,Amy Sambrone,Melissa M. Schutten,Ron Firestein,Ondřej Machoň,Vladimír Kořínek,Edna F. Choo,Dolores Diaz,Mark Merchant,Paul Polakis,Daniel D. Holsworth,Stefan Krauß,Mike Costa	256
7	The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199 2013 ·Drug Metabolism and Disposition ·Edna F. Choo,Jason Boggs,(unknown),Joseph W. Lubach,Nathaniel D. Catron,Gary J. Jenkins,Andrew J. Souers,Richard Voorman	50
8	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts 2013 ·Breast Cancer Research and Treatment ·Inna Y. Gong,Wendy A. Teft,Justin Q. Ly,Yung‐Hsiang Chen,Bruno Alicke,Richard B. Kim,Edna F. Choo	28
9	An Algorithm for Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters 2013 ·Journal of Pharmaceutical Sciences ·Patrick Poulin,Donna M. Dambach,(unknown),Kevin A. Ford,Frank‐Peter Theil,Eric B. Harstad,Jason Halladay,Edna F. Choo,Jason Boggs,Bianca M. Liederer,Brian Dean,Dolores Diaz	9
10	Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response 2012 ·Clinical Cancer Research ·Harvey Wong,Edna F. Choo,Bruno Alicke,Xiao Ding,Hank La,Erin McNamara,Frank‐Peter Theil,Jay Tibbitts,Lori S. Friedman,Cornelis E. C. A. Hop,Stephen E. Gould	96
11	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor 2012 ·Clinical Cancer Research ·Harvey Wong,Laurent Vernillet,Amy Peterson,Joseph A. Ware,Lillian Lee,Jean‐François Martini,Peiwen Yu,Congfen Li,Geoffrey Del Rosario,Edna F. Choo,Klaus P. Hoeflich,Yongchang Shi,Blake T. Aftab,(unknown),(unknown),Marcia Belvin,John Prescott	65
12	Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor 2012 ·Toxicology and Applied Pharmacology ·Dolores Diaz,Kevin A. Ford,Dylan P. Hartley,Eric B. Harstad,Gary Cain,(unknown),Trung Van Nguyen,(unknown),Zhong Zheng,Mark Merchant,Daniel P. Sutherlin,John J. Gaudino,(unknown),(unknown),Edna F. Choo,Bianca M. Liederer,Donna M. Dambach	22
13	PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts 2012 ·Cancer Chemotherapy and Pharmacology ·Edna F. Choo,Chee M. Ng,Leanne Berry,Marcia Belvin,Nicholas Lewin‐Koh,Mark Merchant,Laurent Salphati	26
14	Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments 2011 ·Current Drug Metabolism ·(unknown),Edna F. Choo	23
15	Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process 2011 ·Xenobiotica ·Edna F. Choo,Bruno Alicke,Jason Boggs,(unknown),Stephen E. Gould,Jonas Grina,Kristina West,(unknown),Yingqing Ran,Joachim Rudolph,Steve Wenglowsky	5
16	Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor 2010 ·Xenobiotica ·Edna F. Choo,Marcia Belvin,Jocelyn Chan,Klaus P. Hoeflich,Christine Orr,Kirk Robarge,Xiaoye Yang,Mark Zak,Jason Boggs	17
17	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression 2009 ·Cancer Research ·Klaus P. Hoeflich,Sylvia Herter,Janet Tien,Leo Lap-Yan Wong,Leanne Berry,Jocelyn Chan,Carol O’Brien,Zora Modrušan,Somasekar Seshagiri,Mark R. Lackner,Howard M. Stern,Edna F. Choo,Lesley Murray,Lori S. Friedman,Marcia Belvin	144
18	Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Edna F. Choo,Daniel Kurnik,Mordechai Muszkat,Tadashi Ohkubo,Sheila Shay,James N. Higginbotham,Hartmut Glaeser,Richard B. Kim,Alastair J.J. Wood,G. Wilkinson	64
19	Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species 2004 ·Xenobiotica ·Amit S. Kalgutkar,Edna F. Choo,Tim Taylor,Anthony Marfat	13
20	In vivo inhibition of human CYP1A2 activity by oltipraz 2001 ·Cancer Chemotherapy and Pharmacology ·G. Sofowora,Edna F. Choo,Gail Mayo,Yu Shyr,G. Wilkinson	27

About Edna F. Choo

Edna F. Choo is a scholar working on Pharmacology, Oncology and Molecular Biology, having authored 54 papers that have together received 1.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (20 papers), Pharmacogenetics and Drug Metabolism (12 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). The work is most often cited by research in Pharmacology (286 citations), Oncology (797 citations) and Virology (100 citations). Edna F. Choo has collaborated with scholars based in United States, Canada and France. Frequent co-authors include G. Wilkinson, Richard B. Kim, Alastair J.J. Wood, Hitoshi Imamura, Brenda F. Leake, Jason Boggs, Marcia Belvin, Mark Merchant, Justin Q. Ly and Klaus P. Hoeflich. Their work appears in journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact